secwatch.observer — SEC 8-K summary
======================================

Issuer:     C4 Therapeutics, Inc. (CCCC)
CIK:        0001662579
Form:       8-K
Filed at:   2026-01-14T23:59:59+00:00
Accession:  0001628280-26-002010
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

C4 Therapeutics outlines milestones through 2028; cemsidomide Phase 2 trial on track for Q1 2026
--------------------------------------------------------------------------------

- Cemsidomide Phase 2 MOMENTUM trial to begin Q1 2026; recommended Phase 2 dose 100 µg.
- Phase 1b combination with elranatamab to start Q2 2026; potential accelerated approval path for 4L+ by end 2028.
- Phase 1 data: 40% ORR at 75 µg, 53% ORR at 100 µg in heavily pretreated multiple myeloma patients.
- Cash runway to end 2028 provides funding through key value inflection points including NDA submission.
- Internal discovery strategy targeting inflammation and neurodegeneration; up to 3 IND applications by end 2028.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1662579/000162828026002010/0001628280-26-002010-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1662579/000162828026002010/cccc-20260114.htm
  HTML page:      https://secwatch.observer/filing/0001628280-26-002010

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer